Showing results (121-130 of 161) with videos related to

Sort By:
Pageof 17
Cancer|December 1, 1993
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerationsB L Lum, G A Fisher, N A Brophy, et al.
Transplantation|May 31, 2018
Donating Another Person's Kidney: Avoiding the Discard of Organs by RetransplantationJeffrey L Veale, Erik L Lum, Nicholas G Cowan, et al.
Bone Marrow Transplantation|April 1, 1994
Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimensJ G Bender, L Lum, K L Unverzagt, et al.
Clinical Breast Cancer|March 21, 2009
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approachCarolyn D Britten, Richard S Finn, Linda D Bosserman, et al.
Leukemia & Lymphoma|December 1, 1995
Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantationM Varterasian, V Ratanatharathorn, J P Uberti, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 13, 2017
Association of Citizenship Status With Kidney Transplantation in Medicaid PatientsJenny I Shen, Daniel Hercz, Lilly M Barba, et al.
Cancer Chemotherapy and Pharmacology|December 10, 2015
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancerAngelica L Quartino, Carina Hillenbach, Jing Li, et al.
Transplantation Direct|April 29, 2021
Extremely High Cell-free DNA Levels Observed in Renal Allograft Patient With SARS-CoV-2 InfectionSuphamai Bunnapradist, Nakul Datta, Joanna Schaenman, et al.
Investigational New Drugs|September 1, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancerRanjana Advani, Bert L Lum, George A Fisher, et al.
Cancer|January 13, 2004
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinomaRanjana Advani, Prema Peethambaram, Bert L Lum, et al.
Pageof 17